Pediatrix Medical Group reported third-quarter 2026 net revenue of $501.4 million, up 1.7% from $492.9 million a year earlier, and adjusted EPS of $0.72 versus $0.67. GAAP net income fell to $47.0 million, or $0.59 per diluted share, from $71.7 million, or $0.84, and adjusted EBITDA declined to $85.5 million from $87.3 million. The company also projects full-year 2026 adjusted EBITDA of $290 million to $300 million.
Q3 net revenue $501.4 million vs. $492.9 million in Q3 2025, up 1.7%
Q3 net income $47.0 million ($0.59 diluted EPS) vs. $71.7 million ($0.84), including a $20.9 million investment gain in the prior-year quarter
Q3 adjusted EPS $0.72 vs. $0.67; adjusted EBITDA $85.5 million vs. $87.3 million
Full-year 2026 adjusted EBITDA outlook of $290 million to $300 million
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Pediatrix Medical Group's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$1.91B
-4.9%
$1.94
—
8.6%
FY2024
$2.01B
+0.9%
$-1.19
—
-4.9%
FY2023
$1.99B
+1.1%
$-0.73
-192.4%
-3.0%
FY2022
$1.97B
+3.2%
$0.79
-48.4%
3.4%
FY2021
$1.91B
+10.2%
$1.53
—
6.9%
Frequently asked questions
When is Pediatrix Medical's next earnings date?
Pediatrix Medical has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Pediatrix Medical earn last quarter?
For the quarter ended Sep 2026, Pediatrix Medical reported diluted EPS of $0.59 (-29.8% year over year) on revenue of $501.37M (+1.7%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.